Literature DB >> 8084064

Permissive hypercapnia in acute respiratory failure.

A Bidani1, A E Tzouanakis, V J Cardenas, J B Zwischenberger.   

Abstract

OBJECTIVE: To evaluate the potential efficacy of pressure limitation with permissive hypercapnia in the treatment of acute respiratory failure/adult respiratory distress syndrome on the basis of current theories of ventilator-induced lung injury, potential complications of systemic hypercarbia, and available human outcome studies. DATA SOURCES: Articles were identified through MEDLINE, reference citations of published data, and consultation with authorities in their respective fields. STUDY SELECTION: Animal model experimentation and human clinical trials were selected on the basis of whether they addressed the questions of pressure limitation with or without hypercapnia, the pathophysiologic effects of hypercapnia, or the concept of ventilator-induced parenchymal lung injury. Frequently cited references were preferentially included. DATA EXTRACTION: Data were analyzed with particular emphasis on obtaining the following variables from the clinical studies: peak inspiratory pressures, tidal volumes, minute ventilation, and PCO2. Quantitative aspects of respiratory physiology were used to analyze the theoretical effects of permissive hypercapnia on ventilatory requirements in normal and injured lungs. DATA SYNTHESIS: Extensive animal model data support the hypothesis that ventilator-driven alveolar overdistention can induce significant parenchymal lung injury. The heterogeneous nature of lung injury in adult respiratory distress syndrome, with its small physiologic lung volume, may render the lung susceptible to this type of injury through the use of conventional tidal volumes (10 to 15 mL/kg). Permissive hypercapnia is an approach whereby alveolar overdistention is minimized through either pressure or volume limitation, and the potential deleterious consequences of respiratory acidosis are accepted. Uncontrolled human trials of explicit or implicit permissive hypercapnia have demonstrated improved survival in comparison with models of predictive mortality.
CONCLUSIONS: Avoidance of alveolar overdistention through pressure or volume limitation has significant support based on animal models and computer simulation. Deleterious effects of the associated hypercarbia in severe lung injury do not appear to be a significant limiting factor in preliminary human clinical trials. Although current uncontrolled studies suggest benefit, controlled trials are urgently needed to confirm these findings before adoption of the treatment can be endorsed.

Entities:  

Mesh:

Year:  1994        PMID: 8084064

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  21 in total

Review 1.  Permissive hypercapnia--role in protective lung ventilatory strategies.

Authors:  John G Laffey; Donall O'Croinin; Paul McLoughlin; Brian P Kavanagh
Journal:  Intensive Care Med       Date:  2004-01-14       Impact factor: 17.440

2.  Reduced ventilator pressure and improved P/F ratio during percutaneous arteriovenous carbon dioxide removal for severe respiratory failure.

Authors:  S K Alpard; J B Zwischenberger; W Tao; D J Deyo; A Bidani
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

3.  Hyperoxia during one lung ventilation: inflammatory and oxidative responses.

Authors:  Alicia Olivant Fisher; Kamran Husain; Marla R Wolfson; Terrence L Hubert; Elena Rodriguez; Thomas H Shaffer; Mary C Theroux
Journal:  Pediatr Pulmonol       Date:  2012-03-19

Review 4.  Permissive hypercapnia for the prevention of morbidity and mortality in mechanically ventilated newborn infants.

Authors:  P G Woodgate; M W Davies
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 5.  Is ventilator-induced lung injury a promoter of multiple organ failure in adult respiratory distress syndrome? The effect of permissive hypercapnia on oxygenation and outcome.

Authors:  Keith G Hickling
Journal:  J Anesth       Date:  1997-03       Impact factor: 2.078

6.  Association of bronchopulmonary dysplasia and hypercarbia in ventilated infants with birth weights of 500-1,499 g.

Authors:  Siva Subramanian; Ayman El-Mohandes; Ramasubbareddy Dhanireddy; Matthew A Koch
Journal:  Matern Child Health J       Date:  2011-12

7.  Efficacy of protocolized management for congenital diaphragmatic hernia. a review of 100 cases.

Authors:  Manabu Okawada; Tadaharu Okazaki; Atsuyuki Yamataka; Toshihiro Yanai; Yoshifumi Kato; Hiroyuki Kobayashi; Geoffrey J Lane; Takeshi Miyano
Journal:  Pediatr Surg Int       Date:  2006-11       Impact factor: 1.827

Review 8.  [Diagnosis and therapy of sepsis. Guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine].

Authors:  K Reinhart; F Brunkhorst; H Bone; H Gerlach; M Gründling; G Kreymann; P Kujath; G Marggraf; K Mayer; A Meier-Hellmann; C Peckelsen; C Putensen; M Quintel; M Ragaller; R Rossaint; F Stüber; N Weiler; T Welte; K Werdan
Journal:  Internist (Berl)       Date:  2006-04       Impact factor: 0.743

9.  Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)).

Authors:  K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte
Journal:  Ger Med Sci       Date:  2010-06-28

10.  Adaptive support ventilation with and without end-tidal CO2 closed loop control versus conventional ventilation.

Authors:  Demet S Sulemanji; Andrew Marchese; Marc Wysocki; Robert M Kacmarek
Journal:  Intensive Care Med       Date:  2012-11-14       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.